Alzheimer’s Diagnostics Accelerator Program Awards Nearly $3.5M to Develop Early-detection Methods

Alzheimer’s Diagnostics Accelerator Program Awards Nearly $3.5M to Develop Early-detection Methods
Selected through the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator program, four scientists will share nearly $3.5 million to develop new biomarkers for early detection of Alzheimer’s disease and related dementia. Philanthropists, including ADDF co-founder Leonard Lauder, Bill Gates and Jeff and MacKenzie Bezos, are expected to fund $10 million in ADDF awards this year, and $50 million over the next three years. This first round of awards will focus on biomarkers in the blood, eyes, and other fluids and tissues. Results of a second request for proposals — this one about digital tests — are expected by year’s end. ”After an extensive review, we selected research that showed promise in accelerating the development of innovative diagnostic tools such as blood tests and eye scans,” said a press release statement by Howard Fillit, MD, ADDF founding executive director and chief science officer. “Unlike heart disease and cancer, we lack simple and cost-effective diagnostic to
Subscribe or to access all post and page content.